Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Liver function tests Stories

2014-04-14 10:59:02

Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements. UDCA is the only therapy currently approved to treat PBC. Obeticholic acid at both a 10 mg dose and a 5 mg dose titrated to...

2014-03-13 23:26:09

Liver Cirrhosis Bible & Ezra Protocol, created by Debrea Elkin, is a brand new product that uncovers useful tips on how to cure liver cirrhosis disease. The site Vkool.com published an entire Liver Cirrhosis Bible & Ezra Protocol review, showing readers if this product is worth purchasing. Seattle, Wa (PRWEB) March 13, 2014 Liver cirrhosis is a very common condition in the world, especially in developing countries. It is a result of advanced liver disease. Liver Cirrhosis Bible...

2014-03-11 08:29:53

Funding to support clinical development of treatments for rare cholestatic liver diseases and nonalcoholic steatohepatitis SAN DIEGO, March 11, 2014 /PRNewswire/ -- Lumena Pharmaceuticals (Lumena), a biopharmaceutical company focused on the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, today announced that it has secured $45 million in Series B financing. New Enterprise Associates (NEA) led the financing,...

2013-11-18 08:28:41

Company receives first positive opinion in the European Union for Primary Sclerosing Cholangitis SAN DIEGO, Nov. 18, 2013 /PRNewswire/ -- Lumena Pharmaceuticals, a company developing oral therapeutics for rare liver diseases, today announced that it has received positive opinions for four Orphan Drug Designations by the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) for LUM001. The company's lead drug candidate, LUM001, received the first positive...

2013-11-05 08:34:31

Data Presented Today at Annual Meeting of the American Association for the Study of Liver Diseases in Washington DC Provides Additional Preclinical Validation for LUM001 Currently Being Evaluated in Phase II Studies in Multiple Cholestatic Liver Disease Populations SAN DIEGO, Nov. 5, 2013 /PRNewswire/ -- Lumena Pharmaceuticals, a company developing oral therapeutics for cholestatic liver diseases, today announced that inhibition of the apical sodium-dependent bile acid transporter...

2013-10-01 16:25:54

Data Support Strong Statistical Association of PBC Biochemical Endpoint with Clinical Outcomes NEW YORK, Oct. 1, 2013 /PRNewswire/ -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)(Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases such as primary biliary cirrhosis, today announced that two analyses by the Global Primary Biliary Cirrhosis (PBC) Study Group (also known as the PBC...

2013-09-09 08:51:13

How many breakthrough new drugs never reach patients because tests in clinical trials suggested a high risk of liver damage when the drug actually was quite safe? That question underpins major international research efforts to modernize tests for drug-induced liver injury, mentioned here today at the 246th National Meeting & Exposition of the American Chemical Society (ACS), the world's largest scientific society. The meeting, which features almost 7,000 reports on new discoveries in...

2013-06-10 10:26:15

Helping to protect newborns and older patients against more severe effects of jaundice is the hope of University of Guelph researchers, who have shown how a liver enzyme protects cells from damage caused by the condition. Their discovery might ultimately lead to an alternative treatment for jaundice, such as a new drug or supplement, says Daniel Kim, a research technician in Guelph's Department of Biomedical Sciences. He is lead author of a paper published recently in the journal...

2013-05-08 08:29:58

Funding to support clinical development of drug candidates to treat rare liver diseases SAN DIEGO, May 8, 2013 /PRNewswire/ -- Lumena Pharmaceuticals, a company developing oral therapeutics for rare liver diseases, today announced the company has secured $23 million in Series A financing. Investors include Pappas Ventures, RiverVest Venture Partners and Alta Partners. Founded in 2011 by Pappas Ventures, Lumena will primarily use the funding to advance the clinical development of...

2012-12-06 12:04:53

Each year, about 610,000 Americans suffer their first heart attack, according to the Centers for Disease Control and Prevention. Heart attacks and other symptoms of cardiovascular disease can be caused when blockage occurs in the arteries. In a new study from the University of Missouri, a scientist has discovered a natural defense against arterial blockage: bilirubin. Bilirubin is typically something parents of newborns hear about when their children are diagnosed with jaundice. Generated...